GT Healthcare Capital Partners is an Asia-based private investment partnership focused on healthcare technology and cross-border company growth, with primary-published offices in HongKong and Shanghai. Its mandate supports businesses internationally and their expansion in Asia and GreaterChina. The public portfolio includes AI drug discovery, medical robotics, advanced genomics, diagnostic imaging and neuroscience technology, including Exscientia, Apeiron, Moon Surgical, Oxford Nanopore, Ultromics, Autobahn Therapeutics and OxfordVR. Its current retrieved directory publishes seven professionals, combining investment, clinical and biotechnology experience. Six separately named legal GT investment vehicles are supported by SEC agreements and issuer-regulated holdings disclosures; those documents do not establish final LP sizes or paid capital. The exact corporate manager registration suffix remains unverified, and GTM Capital/MPM-associated vehicles are not assumed to be the same manager. Portfolio therapeutic and product statements are company claims, not proof of medical effectiveness. It is distinct from US GT Capital Partners commercial lending and unrelated GP Healthcare Capital firms.
Founded
2015
Type
Venture capital
Funds6
GT Global Genomics Fund——
Exact GT investment vehicle named in Oxford Nanopore’s issuer RNS1113L major-holdings notice ofDecember28,2022. The notice identifies GT Healthcare Capital Partners at22PottingerStreet,HongKong and names this vehicle in the ownership chain. Voting-rights percentages and notification dates are not LP fundraising amounts or final-close dates. The primary legal name is retained as published; any additional suffix, vehicle-specific final size and cash close remain undisclosed.
GT Global Genomics Fund 2 LP——
Exact GT investment vehicle named in Oxford Nanopore’s issuer RNS1113L major-holdings notice ofDecember28,2022. The notice identifies GT Healthcare Capital Partners at22PottingerStreet,HongKong and names this vehicle in the ownership chain. Voting-rights percentages and notification dates are not LP fundraising amounts or final-close dates. The primary legal name is retained as published; any additional suffix, vehicle-specific final size and cash close remain undisclosed.
GT Healthcare Fund I LP——
Exact GT investment vehicle named in Oxford Nanopore’s issuer RNS1113L major-holdings notice ofDecember28,2022. The notice identifies GT Healthcare Capital Partners at22PottingerStreet,HongKong and names this vehicle in the ownership chain. Voting-rights percentages and notification dates are not LP fundraising amounts or final-close dates. The primary legal name is retained as published; any additional suffix, vehicle-specific final size and cash close remain undisclosed.
GT Healthcare Partners Fund III, L.P.——
Exact Cayman limited-partnership investment vehicle. Boundless Bio’s SEC-filed investors’ rights agreement names it in Schedule A with registered address190ElginAvenue,GrandCayman and GT manager correspondence at22PottingerStreet,HongKong. Exscientia’s SEC-filed shareholder agreement also explicitly defines this vehicle as one component of GT. Separate legal fund, not an alias automatically merged into GT Nextgen Partners Fund III. Final capital raised, cash-called amount and final-close date are not disclosed in the retrieved primary documents.
GT Nextgen Partners Fund III, L.P.——
Exact separately named GT Nextgen investment limited partnership in Boundless Bio’s SEC-filed investors’ rights agreement. Alan Au signs as general partner. Its name is retained distinctly from GT Healthcare Partners Fund III; legal existence and investor-party status do not prove they are identical or establish a final LP close. Fund size, separately paid capital and final-close date remain undisclosed.
GT Nextgen Therapies Fund IV, L.P.——
Exact Cayman limited-partnership investment vehicle named in Boundless Bio and Exscientia SEC-filed agreements. Alan Au signs as general partner in the Boundless agreement, which gives the GT HongKong correspondence address. Cayman regulator lists its registration onMarch23,2021; registration is not a fundraising close. Final size, paid capital and close date are undisclosed in retrieved primary evidence.
Alan AuFounder and Managing Partner
Fred AswadVenture Partner
Lo Yuk LamChairman
Marcus HuiVice President
Mingxi LiPartner
Force Over Mass Capital
OxfordVR£3M · 2018-09-20
Luminous Ventures
Optum Ventures
Oxford University Innovation
ShangBay Capital
ZAP Surgical Systems$81M · 2020-01-08
University of Oxford